The Multiple Myeloma Research Foundation and the Dana-Farber Cancer Institute are pleased to invite you to the inaugural meeting on Advances in Myeloma Precursor Conditions in the 21st Century, taking place on 20th August 2020.
VJHemOnc are official media partners for the meeting, bringing you exclusive coverage of all sessions & panel discussions.
Scientific Committee Chairs: Irene Ghobrial (Co-Lead) USA, Maria-Victoria Mateos (Co-Lead) Spain, Nikhil Munshi USA, Daniel Auclair USA.
8.30AM WELCOME & INTRODUCTION – Meeting Co-chairs 8.35AM Unanswered questions and what is needed over the next 5 years (M. Mateos, I. Ghobrial)
9:00AM TOWARD A BETTER PROGNOSTICATION (Chairs: K. Anderson, other to be announced)
CLINICAL ASPECTS 9:00AM History of MGUS and SMM and prognostic markers (R. Fonseca) 9:15AM Clinical prognostic factors (J. San Miguel)
GENOMICS of SMM 9:30AM Genomic markers using WGS (N. Bolli) 9:45AM Genomic Markers using WES (M. Bustoros/R. Sklavenitis Pistofidis) 10:00AM Molecular timing of initiation: (O. Landgren/F. Maura)
IMMUNE MICROENVIRONMENT of SMM 10:15AM Modeling the immune system in SMM (M. Dhodapkar) 10:30AM Single-cell RNA sequencing of SMM (G. Getz/ N. Haradhvala) 10:45AM Immune profiling in MGUS and SMM (B. Paiva)
11:10AM PANEL DISCUSSION Moderator: D. Auclair, Panel: I. Ghobrial, B. Paiva, M. Dhodapkar, O, Landgren, S. Kumar, N. Munshi, S. Manier, A. Raval, A. Palumbo, others to be announced
11:55AM Interactive poll on their phones/devices
TRIALS AND ENDPOINTS (Working lunch) 12:00PM Innovative endpoints for MM trials (N. Gormley) 12:15PM Phase III trials of SMM (S. Lonial) 12:30PM Antibodies 12:45PM Current ongoing studies of a potential cure for SMM (S. Kumar) 1:00PM Ongoing studies of 3 drug combinations (O. Nadeem)
1:25PM PANEL DISCUSSION Moderator: N. Munshi Panel: M. Mateos, S. Kumar, S. Lonial, F. Gay, C. Tendler, A. Agarwal, T. Facon, S. Noga, others to be announced.
2:10PM Interactive poll on their phones/devices
2:15PM MEETING RECOMMENDATIONS AND NEXT STEPS
VJHemOnc is intended for Healthcare Professionals only
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest hemonc news and updates